Patient Experiences and Perceptions of Living with Refractory Diabetes Mellitus with Insulin Resistance in Japan -A Qualitative Research

Patient Experiences and Perceptions of Living with Refractory Diabetes Mellitus with Insulin Resistance in Japan -A Qualitative Research - Refractory Diabetes Mellitus with Insulin Resistance -Patient Experiences and Perceptions in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043693

Enrollment

Registered

2021-03-22

Start date

2021-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin resistance, lipoatrophic diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients living with insulin resistance or lipoatrophic diabetes mellitus -20+ years of age

Exclusion criteria

Exclusion criteria: -Not eligible at physician's discretion -Patients currently participating in clinical trials on the efficacy and safety of empagliflozin for refractory diabetes mellitus with insulin resistance (conducted by Kobe University with funding and investigational drug provided by Nippon Boehringer Ingelheim [BI] [jRCT2051190029, jRCT2051190094])

Design outcomes

Primary

Measure	Time frame
Information on experiences and perceptions of patients living with insulin resistance or lipoatrophic diabetes mellitus	—

Countries

Japan

Contacts

Public ContactNobutaka Yagi

Nippon Boehringer Ingelheim Co., Ltd. Medicine Division

nobutaka.yagi@boehringer-ingelheim.com03-6417-2043

Outcome results